Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pamela Biondani

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Future Oncology (London, England)|August 23, 2014
Safety profile and treatment response of everolimus in different solid tumors: an observational studyElena Verzoni, Sara Pusceddu, Roberto Buzzoni, et al.
American Journal of Clinical Oncology|February 23, 2013
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II studyEmilio Bajetta, Filippo Pietrantonio, Roberto Buzzoni, et al.
Anticancer Research|April 9, 2013
A review on biomarkers for prediction of treatment outcome in gastric cancerFilippo Pietrantonio, Filippo De Braud, Valentina Da Prat, et al.
Oncology|June 14, 2014
TP53 mutations in advanced colorectal cancer: the dark side of the moonFilippo Pietrantonio, Pamela Biondani, Federica Perrone, et al.
Pathologica|November 17, 2025
HER2-positive neuroendocrine breast carcinoma: a case study uncovers <i>CCND1</i>, <i>FGF19</i>, and <i>IGF1R</i> amplifications as new molecular driversMargherita Zordan, Elena Fiorio, Valeria Maffeis, et al.
Cancer|April 23, 2014
Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group studyEmilio Bajetta, Laura Catena, Nicola Fazio, et al.
Oncology|January 19, 2013
Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?Chiara Bampo, Alessandra Alessi, Simona Fantini, et al.
Medical Oncology (Northwood, London, England)|May 24, 2013
Role of BAX for outcome prediction in gastrointestinal malignanciesFilippo Pietrantonio, Pamela Biondani, Elisa Ciurlia, et al.
International Journal of Cancer|September 16, 2015
Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experienceCarole Helissey, Pamela Biondani, Florian Roquet, et al.
Medical Oncology (Northwood, London, England)|May 25, 2015
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastasesFilippo Pietrantonio, Vincenzo Mazzaferro, Rosalba Miceli, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Future Oncology (London, England)|August 23, 2014
Safety profile and treatment response of everolimus in different solid tumors: an observational studyElena Verzoni, Sara Pusceddu, Roberto Buzzoni, et al.
American Journal of Clinical Oncology|February 23, 2013
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II studyEmilio Bajetta, Filippo Pietrantonio, Roberto Buzzoni, et al.
Anticancer Research|April 9, 2013
A review on biomarkers for prediction of treatment outcome in gastric cancerFilippo Pietrantonio, Filippo De Braud, Valentina Da Prat, et al.
Oncology|June 14, 2014
TP53 mutations in advanced colorectal cancer: the dark side of the moonFilippo Pietrantonio, Pamela Biondani, Federica Perrone, et al.
Pathologica|November 17, 2025
HER2-positive neuroendocrine breast carcinoma: a case study uncovers <i>CCND1</i>, <i>FGF19</i>, and <i>IGF1R</i> amplifications as new molecular driversMargherita Zordan, Elena Fiorio, Valeria Maffeis, et al.
Cancer|April 23, 2014
Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group studyEmilio Bajetta, Laura Catena, Nicola Fazio, et al.
Oncology|January 19, 2013
Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?Chiara Bampo, Alessandra Alessi, Simona Fantini, et al.
Medical Oncology (Northwood, London, England)|May 24, 2013
Role of BAX for outcome prediction in gastrointestinal malignanciesFilippo Pietrantonio, Pamela Biondani, Elisa Ciurlia, et al.
International Journal of Cancer|September 16, 2015
Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experienceCarole Helissey, Pamela Biondani, Florian Roquet, et al.
Medical Oncology (Northwood, London, England)|May 25, 2015
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastasesFilippo Pietrantonio, Vincenzo Mazzaferro, Rosalba Miceli, et al.
Pageof 3